Mouse Anti-LIMD2 Recombinant Antibody (CBYJL-1709) (CBMAB-L1590-YJ)

Hu, H., Wang, Y., Dong, Y., Wang, L., Chen, Y., Zhou, Y., & Sun, L. (2023). Knockdown of LIMD2 inhibits the progression of ovarian carcinoma through ERK1/2 pathway. Molecular Biology Reports, 50(11), 8985-8993.

Zhong, Q. Y., Ying-Wei, X. I. E., Zhi-Liang, C. H. E. N., Yu-Qing, C. H. E. N., Yue-Xin, L. I. U., Wen-Lian, X. I. E., & Wei, Y. A. N. (2022). LIMD2 promotes tumor proliferation, invasion, and epithelial-mesenchymal transition in clear cell renal cell carcinoma. Neoplasma, 69(4).

Chen, L., Qian, J., You, Q., & Ma, J. (2021). LIM domain-containing 2 (LIMD2) promotes the progress of ovarian cancer via the focal adhesion signaling pathway. Bioengineered, 12(2), 10089-10100.

Chen, Y., Huang, X., Zhu, K., Li, C., Peng, H., Chen, L., ... & Xu, Y. (2021). LIMD2 is a prognostic and predictive marker in patients with esophageal cancer based on a cerna network analysis. Frontiers in Genetics, 12, 774432.

Araldi, R. P., de Melo, T. C., Levy, D., de Souza, D. M., Maurício, B., Colozza-Gama, G. A., ... & Cerutti, J. M. (2020). LIMD2 regulates key steps of metastasis cascade in papillary thyroid cancer cells via MAPK crosstalk. Cells, 9(11), 2522.

Zhang, F., Qin, S., Xiao, X., Tan, Y., Hao, P., & Xu, Y. (2019). Overexpression of LIMD2 promotes the progression of non‑small cell lung cancer. Oncology letters, 18(2), 2073-2081.

Pinheiro dos Santos, M. J. C., Bastos, A. U., da Costa, V. R., Delcelo, R., Lindsey, S. C., Colozza-Gama, G. A., ... & Cerutti, J. M. (2018). LIMD2 is overexpressed in BRAF V600E-positive papillary thyroid carcinomas and matched lymph node metastases. Endocrine Pathology, 29, 222-230.

Wang, F., Li, Z., Xu, L., Li, Y., Li, Y., Zhang, X., ... & Liu, D. (2018). LIMD2 targeted by miR‑34a promotes the proliferation and invasion of non‑small cell lung cancer cells. Molecular medicine reports, 18(5), 4760-4766.

Dedhar, S., & Awrey, S. (2018). LIMD2 is an intracellular activator of Integrin Linked Kinase (ILK) activity and GSK‐3/Akt/beta‐catenin signaling. The FASEB Journal, 32, 666-1.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Isotype control